Eric L. Nuermberger
About
Eric L. Nuermberger is a scholar working on Infectious Diseases, Epidemiology and Molecular Biology.
According to data from OpenAlex, Eric L. Nuermberger has authored 169 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 152 papers in Infectious Diseases, 114 papers in Epidemiology and 46 papers in Molecular Biology. Recurrent topics in Eric L. Nuermberger's work include Tuberculosis Research and Epidemiology (144 papers), Mycobacterium research and diagnosis (82 papers) and Cancer therapeutics and mechanisms (38 papers). Eric L. Nuermberger is often cited by papers focused on Tuberculosis Research and Epidemiology (144 papers), Mycobacterium research and diagnosis (82 papers) and Cancer therapeutics and mechanisms (38 papers). Eric L. Nuermberger collaborates with scholars based in United States, South Africa and China. Eric L. Nuermberger's co-authors include J Grosset, William R. Bishai, Sandeep Tyagi, John S. Francis, Rokeya Tasneen, Kathy N. Williams, Nicola M. Zetola, Si-Yang Li, Khisimuzi Mdluli and Paul J. Converse and has published in prestigious journals such as Nature Medicine, Nature Communications and The Journal of Experimental Medicine.
In The Last Decade
Eric L. Nuermberger
167 papers receiving 7.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Eric L. Nuermberger United States | 51 | 6.6k | 4.6k | 2.5k | 1.4k | 878 | 169 | 8.1k | ||
| Véronique Dartois United States | 56 | 6.6k 1.0× | 4.7k 1.0× | 3.8k 1.5× | 1.6k 1.2× | 900 1.0× | 202 | 10.2k | ||
| Emmanuelle Cambau France | 46 | 4.5k 0.7× | 5.0k 1.1× | 2.2k 0.9× | 1.3k 1.0× | 1.7k 1.9× | 148 | 8.3k | ||
| Patrick J. Brennan United States | 39 | 3.4k 0.5× | 4.0k 0.9× | 2.0k 0.8× | 912 0.7× | 728 0.8× | 90 | 10.8k | ||
| Jean‐Luc Mainardi France | 47 | 3.0k 0.5× | 3.2k 0.7× | 1.4k 0.5× | 594 0.4× | 1.4k 1.6× | 173 | 6.7k | ||
| Tawanda Gumbo United States | 48 | 5.5k 0.8× | 4.1k 0.9× | 1.1k 0.4× | 821 0.6× | 1.1k 1.2× | 197 | 7.6k | ||
| Sven Hoffner Sweden | 39 | 5.1k 0.8× | 4.3k 0.9× | 1.8k 0.7× | 1.8k 1.3× | 667 0.8× | 127 | 6.7k | ||
| William Hope United Kingdom | 55 | 7.0k 1.1× | 6.3k 1.4× | 754 0.3× | 281 0.2× | 1.5k 1.7× | 240 | 11.2k | ||
| Max Salfinger United States | 38 | 4.3k 0.7× | 4.1k 0.9× | 723 0.3× | 1.8k 1.3× | 470 0.5× | 113 | 5.7k | ||
| J Grosset France | 58 | 7.9k 1.2× | 7.2k 1.6× | 2.3k 0.9× | 2.6k 1.9× | 1.1k 1.3× | 258 | 10.5k | ||
| Martin J. Boeree Netherlands | 51 | 5.4k 0.8× | 4.9k 1.1× | 910 0.4× | 1.5k 1.1× | 338 0.4× | 165 | 7.4k |
Countries citing papers authored by Eric L. Nuermberger
Since
Specialization
Citations
This map shows the geographic impact of Eric L. Nuermberger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric L. Nuermberger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric L. Nuermberger more than expected).
Fields of papers citing papers by Eric L. Nuermberger
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Eric L. Nuermberger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric L. Nuermberger. The network helps show where Eric L. Nuermberger may publish in the future.
Co-authorship network of co-authors of Eric L. Nuermberger
This figure shows the co-authorship network connecting the top 25 collaborators of Eric L. Nuermberger. A scholar is included among the top collaborators of Eric L. Nuermberger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric L. Nuermberger. Eric L. Nuermberger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Strydom, Natasha, et al.. (2025). Selection and prioritization of candidate combination regimens for the treatment of tuberculosis. Science Translational Medicine. 17(784). eadi4000–eadi4000.
2.
Almeida, Deepak V., et al.. (2023). Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis. Antimicrobial Agents and Chemotherapy. 67(12). e0078923–e0078923.
3.
Bauman, Allison, Karen Rossmassler, Martin I. Voskuil, et al.. (2022). Combination of Mycobacterium tuberculosis RS Ratio and CFU Improves the Ability of Murine Efficacy Experiments to Distinguish between Drug Treatments. Antimicrobial Agents and Chemotherapy. 66(4). e0231021–e0231021.
4.
Xu, Jian, Paul J. Converse, Anna M. Upton, et al.. (2021). Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis. Antimicrobial Agents and Chemotherapy. 65(4). e0141221–e0141221.
5.
Almeida, Deepak V., et al.. (2021). Impact of Dose, Duration, and Immune Status on Efficacy of Ultrashort Telacebec Regimens in Mouse Models of Buruli Ulcer. Antimicrobial Agents and Chemotherapy. 65(11). e0141821–e0141821.
6.
Ammerman, Nicole C., et al.. (2020). Differential In Vitro Activities of Individual Drugs and Bedaquiline-Rifabutin Combinations against Actively Multiplying and Nutrient-Starved Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy. 65(2).
7.
Rifat, Dalin, Si-Yang Li, Thomas R. Ioerger, et al.. (2020). Mutations in fbiD ( Rv2983 ) as a Novel Determinant of Resistance to Pretomanid and Delamanid in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 65(1).
8.
Almeida, Deepak V., Paul J. Converse, Till F. Omansen, et al.. (2020). Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model. Antimicrobial Agents and Chemotherapy. 64(6).
9.
Lee, Brendon M., Liam K. Harold, Deepak V. Almeida, et al.. (2020). Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering. PLoS Pathogens. 16(2). e1008287–e1008287.
10.
Kaushik, Amit, Nicole C. Ammerman, Barry N. Kreiswirth, et al.. (2019). In Vitro Activity of the New β-Lactamase Inhibitors Relebactam and Vaborbactam in Combination with β-Lactams against Mycobacterium abscessus Complex Clinical Isolates. Antimicrobial Agents and Chemotherapy. 63(3).
11.
Kaushik, Amit, Nicole C. Ammerman, Nicole Parrish, & Eric L. Nuermberger. (2019). New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the In Vitro Activity of β-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates. Antimicrobial Agents and Chemotherapy. 63(9).
12.
Deshpande, Devyani, Shashikant Srivastava, Eric L. Nuermberger, et al.. (2018). Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis. Clinical Infectious Diseases. 67(suppl_3). S342–S348.
13.
Omansen, Till F., Deepak V. Almeida, Paul J. Converse, et al.. (2018). High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease. Antimicrobial Agents and Chemotherapy. 63(2).
14.
Zhang, Ming, Si-Yang Li, Ian M. Rosenthal, et al.. (2011). Treatment of Tuberculosis with Rifamycin-containing Regimens in Immune-deficient Mice. American Journal of Respiratory and Critical Care Medicine. 183(9). 1254–1261.
15.
Zhang, Tianyu, Si-Yang Li, Kathy N. Williams, Koen Andries, & Eric L. Nuermberger. (2011). Short-Course Chemotherapy with TMC207 and Rifapentine in a Murine Model of Latent Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine. 184(6). 732–737.
16.
Williams, Kathy N., Steven J. Brickner, C. Kendall Stover, et al.. (2009). Addition of PNU-100480 to First-Line Drugs Shortens the Time Needed to Cure Murine Tuberculosis. American Journal of Respiratory and Critical Care Medicine. 180(4). 371–376.
17.
Zhang, Tianyu, Ming Zhang, Ian M. Rosenthal, J Grosset, & Eric L. Nuermberger. (2009). Short-Course Therapy with Daily Rifapentine in a Murine Model of Latent Tuberculosis Infection. American Journal of Respiratory and Critical Care Medicine. 180(11). 1151–1157.
18.
Tasneen, Rokeya, Sandeep Tyagi, Kathy N. Williams, J Grosset, & Eric L. Nuermberger. (2008). Enhanced Bactericidal Activity of Rifampin and/or Pyrazinamide When Combined with PA-824 in a Murine Model of Tuberculosis. Antimicrobial Agents and Chemotherapy. 52(10). 3664–3668.
19.
Williams, Kathy N., C. Kendall Stover, Tong Zhu, et al.. (2008). Promising Antituberculosis Activity of the Oxazolidinone PNU-100480 Relative to That of Linezolid in a Murine Model. Antimicrobial Agents and Chemotherapy. 53(4). 1314–1319.
20.
Nuermberger, Eric L., Tetsuyuki Yoshimatsu, Sandeep Tyagi, et al.. (2003). Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis. American Journal of Respiratory and Critical Care Medicine. 169(3). 421–426.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Véronique Dartois Breakdown of academic impact, for papers by Emmanuelle Cambau Breakdown of academic impact, for papers by Patrick J. Brennan Breakdown of academic impact, for papers by Jean‐Luc Mainardi Breakdown of academic impact, for papers by Tawanda Gumbo Breakdown of academic impact, for papers by Sven Hoffner Breakdown of academic impact, for papers by William Hope Breakdown of academic impact, for papers by Max Salfinger Breakdown of academic impact, for papers by J Grosset Breakdown of academic impact, for papers by Martin J. Boeree